Addex Reports Q3 2025 Financial Results with CHF 1.58M Net Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Source: Globenewswire
- Revenue Decline: Addex reported Q3 2025 income of CHF 505,800, down CHF 80,000 year-over-year, primarily due to the completion of the R&D collaboration phase with Indivior, impacting revenue streams significantly.
- R&D Expense Reduction: The company incurred R&D expenses of CHF 228,000 in Q3 2025, a slight increase from CHF 204,000 in the same quarter last year, indicating ongoing investment in the GABAB PAM chronic cough clinical candidate despite the completion of earlier phases.
- Widening Net Loss: As of September 30, 2025, Addex's net loss reached CHF 1.577 million, an increase of CHF 49,000 from CHF 1.528 million in the prior year, primarily driven by increased losses from its investment in Neurosterix US Holdings LLC.
- Cash Flow Situation: Cash and cash equivalents decreased to CHF 2.187 million as of September 30, 2025, down CHF 1.162 million from CHF 3.349 million a year earlier, reflecting cash outflow pressures from operational activities.
Analyst Views on ADXN
About ADXN
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
